TARS vs RXST

For growth investors, Tarsus Pharmaceuticals, Inc.

(TARS) is the stronger pick with 146. 7% revenue growth year-over-year, versus -3. 9% for RxSight, Inc. (RXST). Analysts rate Tarsus Pharmaceuticals, Inc. (TARS) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Tarsus Pharmaceuticals, Inc.

(TARS) delivered a total return of +113. 3%, compared to -63. 7% for RxSight, Inc. (RXST). Over 10 years, the gap is even starker: TARS returned +210. 8% versus RXST's -63. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Tarsus Pharmaceuticals, Inc.

(TARS) is the lower-risk stock at 0. 65β versus RxSight, Inc. 's 1. 73β — meaning RXST is approximately 166% more volatile than TARS relative to the S&P 500. On balance sheet safety, RxSight, Inc. (RXST) carries a lower debt/equity ratio of 4% versus 27% for Tarsus Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Tarsus Pharmaceuticals, Inc.

(TARS) is pulling ahead at 146. 7% versus -3. 9% for RxSight, Inc. (RXST). On earnings-per-share growth, the picture is similar: Tarsus Pharmaceuticals, Inc. grew EPS 48. 2% year-over-year, compared to -33. 8% for RxSight, Inc.. Over a 3-year CAGR, TARS leads at 159. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Tarsus Pharmaceuticals, Inc.

(TARS) is the more profitable company, earning -14. 7% net margin versus -29. 0% for RxSight, Inc. — meaning it keeps -14. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TARS leads at -15. 7% versus -35. 8% for RXST. At the gross margin level — before operating expenses — TARS leads at 93. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Tarsus Pharmaceuticals, Inc.

(TARS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65), +210. 8% 10Y return). RxSight, Inc. (RXST) carries a higher beta of 1. 73 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TARS: +210. 8%, RXST: -63. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TARS is a small-cap high-growth stock; RXST is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.